148 related articles for article (PubMed ID: 32314727)
81. Systemic lupus erythematosus associated with acute parvovirus B19 infection.
Díaz F; Collazos J; Mendoza F; De La Viuda JM; Cazallas J; Urkijo JC; Flores M
Clin Microbiol Infect; 2002 Feb; 8(2):115-7. PubMed ID: 11952726
[TBL] [Abstract][Full Text] [Related]
82. Parvovirus B19 detection analysis in thyroid tissue paired samples: an observational study from a tertiary surgical oncology department.
Nasikas D; Zafiropoulos A; K Symvoulakis E; Bertsias A; Derdas S; A Spandidos D; Sakorafas G; Sourvinos G
J BUON; 2021; 26(3):1016-1021. PubMed ID: 34268967
[TBL] [Abstract][Full Text] [Related]
83. Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus.
Fawaz-Estrup F
J Rheumatol; 1996 Jul; 23(7):1180-5. PubMed ID: 8823689
[TBL] [Abstract][Full Text] [Related]
84. Two-year follow-up study after human parvovirus B19 infection.
Seishima M; Oyama Z; Yamamura M
Dermatology; 2003; 206(3):192-6. PubMed ID: 12673074
[TBL] [Abstract][Full Text] [Related]
85. Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease.
Karrasch M; Schmidt V; Hammer A; Hochhaus A; Rosée P; Petersen I; Sauerbrei A; Baier M; Sayer HG; Hermann B
Hematology; 2017 Mar; 22(2):93-98. PubMed ID: 27311084
[TBL] [Abstract][Full Text] [Related]
86. The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome.
Chen DY; Tzang BS; Chen YM; Lan JL; Tsai CC; Hsu TC
Clin Chim Acta; 2010 Aug; 411(15-16):1084-9. PubMed ID: 20385113
[TBL] [Abstract][Full Text] [Related]
87. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy.
Moudgil A; Nast CC; Bagga A; Wei L; Nurmamet A; Cohen AH; Jordan SC; Toyoda M
Kidney Int; 2001 Jun; 59(6):2126-33. PubMed ID: 11380814
[TBL] [Abstract][Full Text] [Related]
88. Parvovirus B19 infection in patients with rheumatoid arthritis in Taiwan.
Chen YS; Chou PH; Li SN; Tsai WC; Lin KH; Tsai KB; Yen JH; Liu HW
J Rheumatol; 2006 May; 33(5):887-91. PubMed ID: 16511938
[TBL] [Abstract][Full Text] [Related]
89. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus.
Loizou S; Cazabon JK; Walport MJ; Tait D; So AK
Arthritis Rheum; 1997 Jan; 40(1):103-8. PubMed ID: 9008606
[TBL] [Abstract][Full Text] [Related]
90. CASE OF HASHIMOTO'S DISEASE WITH MYASTHENIA GRAVIS.
DALY JJ; JACKSON E
Br Med J; 1964 Mar; 1(5385):748. PubMed ID: 14102022
[No Abstract] [Full Text] [Related]
91. Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human parvovirus B19 VP1 unique region protein.
Tzang BS; Lee YJ; Yang TP; Tsay GJ; Shi JY; Tsai CC; Hsu TC
Clin Chim Acta; 2007 Jul; 382(1-2):31-6. PubMed ID: 17451664
[TBL] [Abstract][Full Text] [Related]
92. Human Endogenous Retroviral Genetic Element With Immunosuppressive Activity in Both Human Autoimmune Diseases and Experimental Arthritis.
Laska MJ; Troldborg A; Hauge EM; Bahrami S; Stengaard-Pedersen K
Arthritis Rheumatol; 2017 Feb; 69(2):398-409. PubMed ID: 27696782
[TBL] [Abstract][Full Text] [Related]
93. Association of systemic and thyroid autoimmune diseases.
Biró E; Szekanecz Z; Czirják L; Dankó K; Kiss E; Szabó NA; Szucs G; Zeher M; Bodolay E; Szegedi G; Bakó G
Clin Rheumatol; 2006 Mar; 25(2):240-5. PubMed ID: 16247581
[TBL] [Abstract][Full Text] [Related]
94. Clinical and molecular evidence for association of SLE with parvovirus B19.
Pavlovic M; Kats A; Cavallo M; Shoenfeld Y
Lupus; 2010 Jun; 19(7):783-92. PubMed ID: 20511275
[TBL] [Abstract][Full Text] [Related]
95. The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production.
Tzang BS; Tsay GJ; Lee YJ; Li C; Sun YS; Hsu TC
Clin Chim Acta; 2007 Mar; 378(1-2):59-65. PubMed ID: 17169353
[TBL] [Abstract][Full Text] [Related]
96. Clinical utility of immune function based on IFN-γ monitoring of lymphocyte subsets for parvovirus B19 infection in renal recipients.
Zhang QQ; Zhang WJ; Wang F; Chen S; Chang S
Infect Genet Evol; 2022 Sep; 103():105307. PubMed ID: 35738549
[TBL] [Abstract][Full Text] [Related]
97. Persistence of parvovirus B19 in synovial fluid and bone marrow.
Nikkari S; Roivainen A; Hannonen P; Möttönen T; Luukkainen R; Yli-Jama T; Toivanen P
Ann Rheum Dis; 1995 Jul; 54(7):597-600. PubMed ID: 7668905
[TBL] [Abstract][Full Text] [Related]
98. Thymectomy and systemic lupus erythematosus (SLE).
Panarese A; D'Andrea V; Pironi D; Filippini A
Ann Ital Chir; 2014; 85(6):617-8. PubMed ID: 25919914
[TBL] [Abstract][Full Text] [Related]
99. Glycosylation in Autoimmune Diseases.
Ząbczyńska M; Link-Lenczowski P; Pocheć E
Adv Exp Med Biol; 2021; 1325():205-218. PubMed ID: 34495537
[TBL] [Abstract][Full Text] [Related]
100. Status of immunity against PVB19 in HIV-infected patients according to CD4(+) cell count, and antiretroviral therapy regimen groups.
Abdollahi A; Shoar S; Sheikhbahaei S; Mahdaviani B; Rasoulinejad M
Niger Med J; 2014 Jan; 55(1):20-3. PubMed ID: 24970964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
